Rare Variants Associated With Interval Breast Cancers

Though common breast cancer variants indicate increased breast cancer risk, certain rare variants are associated with an increased risk for interval breast cancers and death, according to a study published in the Nov. 1 issue of Cancer Research.
Jingmei Li, Ph.D., from the Genome Institute of Singapore, and colleagues assessed whether the genetic risk stratification of breast cancer by rare and common variants in established loci can discriminate tumors with different biology, patient survival, and mode of detection among 5,099 patients with breast cancer diagnosed in Sweden between 2001 and 2008. The genetic risk load was evaluated through protein-truncating variant (PTV) carriership in 31 breast cancer predisposition genes or polygenic risk score (PRS) using 162 single-nucleotide polymorphisms.
The researchers found that PTV carriers (597 patients) were younger and were associated with more aggressive tumor phenotypes (estrogen receptor-negative, large size, high grade, high proliferation, luminal B, and basal-like subtype) and worse outcome (hazard ratio [HR], 1.65) versus noncarriers. PTV carriership remained associated with high grade and worse survival (HR, 1.76) even after 92 BRCA1/2 carriers were excluded. Higher PRS was associated with less aggressive tumor characteristics (estrogen receptor-positive, progesterone receptor-positive, small size, low grade, low proliferation, and luminal A subtype) in BRCA1/2 noncarriers. In women with low mammographic density, non-BRCA1/2 PTV carriers more often had interval than screen-detected disease (odds ratio, 1.89), but higher PRS was associated with a lower risk for interval-detected versus screen-detected cancer (odds ratio, 0.77).
"These findings offer the potential to improve screening practices for breast cancer by providing a deeper understanding of how risk variants affect disease progression and mode of detection," the authors write.
Looking for chemical products? Let suppliers reach out to you!
2026-07-16
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Nuohui Health tore off the 'B label', the beginning of China's cancer early screening industry to regain confidence
-
The female Jobs $9 billion scam failed, is the 'drop blood cancer test' a shocking scam, or a ray of hope?
-
L’ORÉAL SUED OVER HAIR STRAIGHTENING-PRODUCTS CANCER CLAIMS
-
Will the mRNA cancer vaccine come true?
-
Genentech Team Discovers New Cancer Immunotherapy Target - ESCRT
-
China Small Molecule Innovative Drugs Industry Trends to 2022
-
Prevent Diseases: Osimertinib Mechanism of Action
-
The European Union completely banned ranitidine or carcinogens
-
Study: Diet with fiber & yogurt may reduce lung cancer risk
-
A new generation of antibody-drug conjugates for cancer patients
Recommend Reading
-
NHU and Sinopec Advance Liquid Methionine Project
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
Polyester Bottle Flakes Soared This Week, Then Fell Back from High Levels
-
Polyethylene Rides High, Price Fluctuations Limited
-
WACKER’s 2025 Loss Reaches €805 Million as the PACE Cost-Cutting Plan Becomes the Key Variable for 2026
-
USDA Puts Fresh Money Into Local Food Markets
-
Ethylene Glycol Prices Soar by 36.12% in March